image credit- shutterstock
BioDuro is expanding its global contract research, development and manufacturing organisation (CRDMO) network with the opening of a new drug substance R&D and manufacturing campus in Bengbu, China.
Additionally, high-potency labs and peptide scale-up synthesis facilities are being added to two Shanghai campuses. These developments significantly increase the company’s capacity and capabilities to meet the growing demand for scalable and integrated solutions for small molecules, peptides, and complex conjugated drugs in the biopharmaceutical industry.
The newly established Bengbu campus, set to begin operations in September 2025, will strengthen drug substance manufacturing capabilities, particularly for large-scale commercial production of regulatory starting material (RSM). This investment responds to the increasing need for drug substance manufacturing capacities as pharmaceutical projects progress through clinical trials and toward commercialisation.
The facility features 130,000 litres of total reactor volume distributed across eight manufacturing lines, with individual reactors reaching up to 15,000 liters. This capacity will support the production of RSMs and advanced intermediates, enabling the company to support drug substance projects from Phase I through commercial supply. An integrated process R&D centre, accommodating 150+ chemists, will be co-located on-site to facilitate process development, optimisation, and scale-up, ensuring efficient technology transfer and project execution.
